1
From a doctor and a pharmacy
A clinician writes a prescription. A licensed pharmacy fills it. Insulin, semaglutide, tirzepatide, tesamorelin, teriparatide, oxytocin, and bremelanotide exist this way — label, evidence, and recall together.
Sourcing
Sourcing peptides: pathways, payment, and risks
A pharmacy, a compounding bench, a trial, and a website vial are four different objects. Insurance follows the label.
1
The four pathways
If someone says they can get you peptides, ask which of these four they mean. That answer decides whether a doctor, an insurer, or nobody stands behind the vial.
2
Mixed at a compounding pharmacy
Allowed when an approved product cannot meet a documented medical need. Ingredients must be eligible. A 2026 advisory-committee vote is a suggestion to FDA — not a listing, and not an approval.
3
In a research trial
Peptides still being studied — retatrutide, elamipretide, some kisspeptin protocols — belong in a trial, with monitoring. That is how you get the product the paper used.
4
From a website or unofficial clinic
Some sites and cash clinics sell powder labeled “not for human consumption.” That label means the seller is not standing behind it as a medicine. Strand will not name vendors.
2
Will insurance pay?
Insurance pays for a labeled medicine, not a sequence name. A diabetes drug is not automatically a weight-loss drug. A research chemical has no product number, so there is nothing to claim.
- It depends on what the drug is for
- The same semaglutide molecule is a diabetes drug (Ozempic) or a weight-loss drug (Wegovy). Plans pay for the use written on the label. A clinic “microdose” is not a covered use.
- You will probably need approval first
- Insurers often ask for BMI, A1c, or proof that a cheaper drug was tried. A denial is a contract decision, not a medical diagnosis.
- Medicare and weight-loss drugs (2026–2027)
- From 1 July 2026 through 31 December 2027, some people with Medicare Part D can get Wegovy, Zepbound KwikPen, or Foundayo for $50 a month. Single-dose Zepbound vials are not in that program. Diabetes coverage of Ozempic or Mounjaro is a separate question.
- Some drugs only come from specialty pharmacies
- Tesamorelin, teriparatide, and similar medicines go through specialty pharmacies, extra paperwork, and time limits.
- What insurance never covers
- Research chemicals, vials labeled “not for human use,” cash peptide stacks, and most compounded copies of approved weight-loss drugs after the shortage ended. No approved product number, no claim.
Official pages: Medicare weight-loss drugs · CMS $50/month program. Always check your own plan.
3
The grey market
When FDA made many research peptides hard to compound in 2023, demand moved to websites, cash clinics, and social-media pens. A July 2026 advisory vote on compounding is not an approval. It does not make an unlabeled vial safe.
It may not be what the label says
Tests of similar “research chemical” markets have found the wrong substance, a weaker dose, or no peptide at all. A sequence on a website is a claim.
It may not be clean
Vials mixed on a kitchen counter are not made in a sterile pharmacy. Bacteria in a multi-use vial can cause abscesses and bloodstream infections.
It can trigger the immune system
Clumps and leftover chemicals in the powder can train the body against the peptide. FDA has flagged this for several compounding nominations.
Fake pens exist
Counterfeit Ozempic-like pens have been found in the US. A cheap pen from social media is not a coupon.
It may break drug law
Selling an unapproved peptide for human use is selling an unapproved drug. Buyers are usually not the ones fined first — they are the ones holding an unlabeled injectable if something goes wrong.
It can get athletes banned
Sport’s anti-doping list bans growth-hormone secretagogues, GH fragments, and thymosin beta-4. A research vial is still a failed test.
4
What can go wrong
- From the drug itself. Nausea and gallbladder problems on weight-loss shots. Low blood sugar on insulin. Swelling on growth-hormone cousins. These are on the labels when a label exists.
- From a bad product. Wrong salt, wrong sequence, bacteria, fake pens. Trials never measured those.
- From the immune system. Impurities can raise antibodies. FDA has written this down.
- From using it for the wrong reason. A diabetes drug as a cosmetic, or a gut peptide as a tendon drug, is an experiment on one person.
- From sport and the law. Unapproved drugs. Bans for testers.
Every peptide record uses this same order: pathway, insurance, grey market, risks, papers.